Full Text of PDF (389k)
Article in Japanese
Abstract
Case Report
A case of EGFR G719A mutation-positive lung adenocarcinoma with leptomeningeal carcinomatosis successfully treated with afatinib
Haruka Kanesada Yoshihiro Taguchi Takuyuki Koda Kotaro Kaziwara Hideki Makino Takanori Kanematsu
Respiratory-Center, Matsuyama Red Cross Hospital
ABSTRACT
We herein report a case of a 53-year-old woman who was diagnosed with adenocarcinoma of the lung with brain metastases and G719A epidermal growth factor receptor mutation. She experienced headaches and nausea in May 20XX. Contrast-enhanced magnetic resonance imaging (MRI) of the head revealed abnormal leptomeningeal enhancement on the brain surface. Cytology of cerebrospinal fluid (CSF) revealed adenocarcinoma, and she was diagnosed with leptomeningeal carcinomatosis. She was treated with afatinib, and the neurological symptoms improved from day three. On contrast-enhanced MRI scan, the area of abnormal leptomeningeal enhancement had reduced, and cytological examination of CSF was negative for three months. The CSF penetration rate of afatinib was 0.17%. Her leptomeningeal carcinomatosis was controlled, which improved prognosis and performance statu
KEYWORDS
Lung adenocarcinoma EGFR G719A mutation Leptomeningeal carcinomatosis Afatinib Cerebrospinal fluid (CSF) penetration rate
Received 23 Oct 2019 ／ Accepted 7 Feb 2020
AJRS, 9(3): 183-186, 2020
Copyright © The Japanese Respiratory Society All Rights Reserved.